Format

Send to

Choose Destination
J Cell Physiol. 2015 Nov;230(11):2598-605. doi: 10.1002/jcp.25016.

Treg(s) in Cancer: Friends or Foe?

Author information

1
Medical Clinic 3, Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
2
Department of Hematology and Oncology, Internal Medicine 5, Medical University Innsbruck, Innsbruck, Austria.
3
Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria.

Abstract

Immune escape is a hallmark of cancer. Regulatory T cells (Treg) have been described to maintain peripheral tolerance. The role of Treg in cancer is ambiguous, as they are central inhibitory regulators in solid tumors, whereas during inflammation-driven tumorigenesis they prevent cancer initiation by restraining inflammation. As a consequence, under conditions with chronic inflammation that may initiate malignant transformation, application rather than depletion of Treg may be helpful. In solid tumors, however, the success story of immune-activating antibodies targeting checkpoint molecules of T cell activation fuels the hope that Treg inactivation or depletion may additionally boost anti-tumor immune response. In this review we summarize important aspects on the dual role of Treg in cancer to provide a rationale for future Treg targeting attempts.

PMID:
25913194
DOI:
10.1002/jcp.25016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center